{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053900","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.537063+00:00","generated_at":"2026-06-02T18:57:44.112470+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IDEAYA Q1 net loss $39.6M, cash $941M; darovasertib UM data at ASCO, Werner IND on track","bullets":["Net loss of $39.6M for Q1 2024; cash, equivalents and marketable securities $941.4M, projected to fund operations into 2028.","Darovasertib neoadjuvant UM Phase 2 IST oral presentation at ASCO 2024; company-sponsored update on >30 patients and FDA guidance targeted H2 2024.","Selected Phase 2 dose for IDE397 in MTAP-deletion squamous NSCLC based on multiple PRs by RECIST 1.1; multiple PRs also in MTAP bladder cancer.","IND-enabling GLP tox completed for Werner Helicase inhibitor with GSK; IND filing targeted H2 2024 as 5th first-in-class clinical program.","Targeting FPI for IDE397+Trodelvy in MTAP bladder cancer mid-2024; Phase 2 expansion for IDE161 in HRD and combo with KEYTRUDA in endometrial cancer in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053900","json":"https://secwatch.observer/filing/0000950170-24-053900.json","markdown":"https://secwatch.observer/filing/0000950170-24-053900.md","text":"https://secwatch.observer/filing/0000950170-24-053900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024053900/0000950170-24-053900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024053900/idya-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:57:44.112470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37d0d70fe83494db97de21ff1cd5b2b1bcbf7b3f","claim":"IDEAYA Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 7, 2024, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024053900/0000950170-24-053900-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}